(Q34266258)

1 August 2017

1 reference

title

Treatment of dementia with neurotransmission modulation (English)

1 reference

1 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1633

16 March 2024

author name string

Suzanne Evans

2

1 reference

1 August 2017

Sheila A. Doggrell

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14519085

16 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

full work available at URL

1 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/13543784.12.10.1633

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1633

Expert Opinion on Investigational Drugs

16 March 2024

published in

1 reference

1 August 2017

volume

12

1 reference

1 August 2017

issue

10

1 reference

1 August 2017

page(s)

1633-1654

1 reference

The cost of institutional care in Alzheimer's disease: nursing home and hospital use in a prospective cohort

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Mixed dementia: epidemiology, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Tacrine therapy is associated with reduced mortality in nursing home residents with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Donepezil treatment of vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Galantamine blocks delayed rectifier, but not transient outward potassium current in rat dissociated hippocampal pyramidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

The effects of some K(+) channel blockers on scopolamine- or electroconvulsive shock-induced amnesia in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Nicotinic receptors in aging and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Suppressed expression of nicotinic acetylcholine receptors by nanomolar beta-amyloid peptides in PC12 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Effects of the nootropic drug nefiracetam on the GABAA receptor-channel complex in dorsal root ganglion neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Improvement by nefiracetam of beta-amyloid-(1-42)-induced learning and memory impairments in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies-an immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Discovery of a highly potent, functionally-selective muscarinic M1 agonist, WAY-132983 using rational drug design and receptor modelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Binding sites for [3H]AF-DX 116 and effect of AF-DX 116 on endogenous acetylcholine release from rat brain slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

SCH 57790: a novel M2 receptor selective antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Role of serotonin in the behavioral and psychological symptoms of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Localization and possible functions of presenilins in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Role of serotonin in memory impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Perturbed dentate gyrus function in serotonin 5-HT2C receptor mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

The quipazine- and TFMPP-increased conditioned avoidance response in rats: role of 5HT1C/5-HT2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Quantitative autoradiography of 5-HT4 receptors in brains of three species using two structurally distinct radioligands, [3H]GR113808 and [3H]BIMU-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Lesion study of the distribution of serotonin 5-HT4 receptors in rat basal ganglia and hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

21 January 2018

Central 5-HT4 receptors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Serotonin receptors in cognitive behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

(S)-WAY 100135, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

8-OH-DPAT impairs spatial but not visual learning in a water maze by stimulating 5-HT1A receptors in the hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Involvement of the serotonergic type 1A (5-HT1A) receptor in the agranular insular cortex in the consolidation of memory for inhibitory avoidance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal administration of scopolamine or 7-chloro-kynurenic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by blockade of hippocampal NMDA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

5HT antagonists attenuate MK801-impaired radial arm maze performance in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Ondansetron improves cognitive performance in the Morris water maze spatial navigation task.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Different effects of tropisetron and ondansetron in learning and memory paradigms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

5-HT4 receptors improve social olfactory memory in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Immunohistochemical distribution of somatostatin-like immunoreactivity in the central nervous system of the adult rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Somatostatin augments long-term potentiation of the mossy fiber-CA3 system in guinea-pig hippocampal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Possible involvement of brain somatostatin in the memory formation of rats and the cognitive enhancing action of FR121196 in passive avoidance task

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

FK960, a potential anti-dementia drug, increases synaptic density in the hippocampal CA3 region of aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Role of glial glutamate transporters in the facilitatory action of FK960 on hippocampal neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

The central noradrenaline system and memory consolidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Noradrenergic changes, aggressive behavior, and cognition in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Clonidine impairs sustained attention and memory in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Actions of alpha-2 noradrenergic agonists on spatial working memory and blood pressure in rhesus monkeys appear to be mediated by the same receptor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1633

Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells

21 January 2018

8

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1633

Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type.

16 March 2024

14

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1633

Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease.

16 March 2024

30

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1633

Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine

16 March 2024

48

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1633

AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats.

16 March 2024

56

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1633

Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease.

16 March 2024

66

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1633

Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired.

16 March 2024

77

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1633

Theta-frequency synaptic potentiation in CA1 in vitro distinguishes cognitively impaired from unimpaired aged Fischer 344 rats.

16 March 2024

79

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1633

Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine.

16 March 2024

130

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1633

16 March 2024

Identifiers

1 reference

1 August 2017

1 reference